June 14, 2024
Renovaro, Inc. Announces $10 million in Equity Committed
“We appreciate confidence in the Company demonstrated by the investors,” said the Hon. Mark Dybul, MD, CEO.
May 24, 2024
Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy
This collaboration would bring together Renovaro's proprietary cancer vaccine technology and the Cancer Center's expertise in several ancillary immunomodulatory technologies, towards innovative advancements in cancer treatment.
April 30, 2024
Transforming Cancer Detection: RenovaroCube Introduces Flamingo, a novel AI model based on Fragmentomics
April 29, 2024
Avram Miller Talks About Renovaro And Its Impact In Diagnosing Cancers and Infectious Diseases With AI
The potential impact of AI on healthcare is vast and transformative. With the use of AI platforms for diagnosing diseases like cancer, we can expect improved accuracy, efficiency, and outcomes in patient care. Renovaro stands at the forefront of this innovative shift towards a more intelligent healthcare system powered by artificial intelligence.
April 24, 2024
RenovaroCube to Acquire 100% Ownership of Cyclomics
RenovaroCube has entered into an amendment to its binding letter of intent to acquire 100% ownership of Cyclomics, further cementing their shared commitment to advancing state-of-the-art technologies in cancer diagnostics and treatment.
April 18, 2024
Renovaro Inc. Proudly Announces the Appointment Of Professor Dr. Geert Kazemier as the Chairman of its Scientific Advisory Board
This pivotal move signifies a major leap forward in Renovaro’s quest to redefine cancer diagnosis and treatment through cutting-edge AI and immunotherapy technologies.
February 14, 2024
Statement of Renovaro Inc
We felt compelled to comment on the shorter Hindenburg’s opinion piece.
February 13, 2024
Cutting Edge AI Company GEDiCube and Cyclomics sign binding LOI to join forces and position themselves at the forefront of the global liquid biopsy marketplace
A Binding LOI has been executed: GEDiCube will acquire 75% of Cyclomics at Closing.
February 13, 2024
AI Pioneer GEDiCube and Biotech Innovator Renovaro Biosciences Combine Forces to Accelerate Personalized Medicine
“We believe this combination marks a significant milestone in the journey of personalized medicine,”
January 25, 2024
Results Shareholders Meeting
All of the matters put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated January 3, 2024, were approved by the requisite number of votes cast at the meeting.